Coinbase says AI writes most code
Coinbase said artificial intelligence now generates more than 95% of the code written across the company.
Jon Cuthbert
Founder & COOJon is a former international magazine editor with a strong background in business publications (print and digital) in the Middle East and Australia.
Contact
Contact editorial teamArticles by Jon Cuthbert
Alfabs Australia cuts net debt to millions
Alfabs Australia (ASX:AAL) has reduced its net debt to $36.6 million and generated positive free cash flow in its Q4 FY26 operational update.
Cryptocurrency
Senators oppose Senate vote on CLARITY Act
A group of US senators has urged Senate leaders to delay consideration of the CLARITY Act, arguing the bill needs stronger investor protections.
Cryptocurrency
Humanity Protocol confirms $36M wallet breach
Humanity Protocol confirmed hackers stole about US$36 million from one of its operational wallets.
Predictive Discovery invests US$10M in Awalé Resources
Predictive Discovery (ASX:PDI) agreed to a US$10 million strategic investment to acquire around a 12.3% stake in Awalé Resources.
US and UK tighten tokenised finance rules
US and UK regulators are moving ahead with new rules to support tokenised finance and digital assets.
Technology
Meta faces AI layoff lawsuit from 26 employees
Meta Platforms (NASDAQ:META) was sued by 26 current and former employees who allege its AI-assisted layoff process disproportionately selected workers with disabilities or protected leave.
Hemab Therapeutics presents positive sutacimig data
Hemab Therapeutics (NASDAQ:COAG) shared Phase 2 long-term extension data for its drug candidate sutacimig, which demonstrated sustained prophylactic bleed reduction across 34 patients with Glanzmann thrombasthenia.
Technology
Xanadu and Lockheed Martin expand quantum training
Xanadu (NASDAQ:XNDU) and Lockheed Martin (NYSE:LMT) announced a strategic collaboration to expand internal quantum programming training.
NextCure backs Avere merger with $320 million financing
NextCure (NASDAQ:NXTC) agreed to merge with privately held Avere Therapeutics in an all-stock transaction supported by a concurrent $320 million private placement.